Based on this lukewarm recommendation, Canadian regulators approved Prochymal on May 17 with conditions that restricts use of the stem cell therapy and requires Osiris to provide further clinical data to prove its clinical benefit.
This is not the ringing endorsement of Prochymal that Osiris has portrayed since the Canadian approval was announced last month. A read of the Prochymal label approved in Canada makes that point clear.
"Protocol 280" was a double-blind, placebo-controlled phase III study that enrolled 240 patients with steroid-refractory GVHD. In 2009, Osiris announced that the "protocol 280" study failed, as did a companion phase III study in newly diagnosed GVHD patients. Prochymal provided little or no benefit over placebo.
Osiris, however, sifted through the negative phase III study to find a subgroup of 28 children with all grades of GVHD --14 treated with Prochymal and 14 with a placebo. In this retrospectively defined subgroup, the Prochymal response rate at day 28 was 64% versus 36% for the placebo-treated patients -- a trend favoring Prochymal but not statistically significant.The survival data from this data-mined subgroup of children is equally weak. At day 100, 11 Prochymal patients (78.6%) were alive compared to seven placebo-treated patients (50%). The result was not statistically significant. At day 180, the survival "benefit" narrows, with nine Prochymal-treated kids alive versus seven placebo-treated kids. Health Canada also considered data from "Protocol 275," a single-arm (uncontrolled) study of 75 pediatric patients with Grades B-D acute GVHD who failed to respond to other treatments.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts